atorvastatin has been researched along with darapladib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballantyne, CM; Davidson, MH; Hanefeld, M; Johnson, JL; Mohler, ER; Ruilope, LM; Zalewski, A | 1 |
| Corson, MA | 1 |
| Braunwald, E; Cannon, CP; Daga, S; Dalby, AJ; Eisen, A; Goodrich, EL; Im, K; Lukas, MA; O'Donoghue, ML; Spinar, J; Steen, DL; Zhou, J | 1 |
1 trial(s) available for atorvastatin and darapladib
| Article | Year |
|---|---|
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Benzaldehydes; Biomarkers; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukins; Male; Middle Aged; Oximes; Prognosis; Pyrroles; Recurrence; Risk Factors | 2008 |
2 other study(ies) available for atorvastatin and darapladib
| Article | Year |
|---|---|
Phospholipase A2 inhibitors in atherosclerosis: the race is on.
Topics: Atorvastatin; Benzaldehydes; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oximes; Phospholipases A2, Secretory; Pyrroles | 2009 |
Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Atorvastatin; Benzaldehydes; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Oximes; Phospholipase A2 Inhibitors; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Renal Insufficiency; Rosuvastatin Calcium; Secondary Prevention; Sex Factors; Simvastatin | 2017 |